Commodore Capital LP Iveric Bio, Inc. Transaction History

Commodore Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $1.78 Million - $3.69 Million	195,000 Added 8.8%	2,409,961 $23.2 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $12.2 Million - $16.9 Million	-1,002,202 Reduced 31.15%	2,214,961 $37.3 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $6.46 Million - $8.77 Million	467,026 Added 16.98%	3,217,163 $53.8 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $7.08 Million - $17.5 Million	1,001,896 Added 57.31%	2,750,137 $44.7 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $109,248 - $137,664	19,200 Added 1.11%	1,748,241 $11 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $2.31 Million - $3.13 Million	454,780 Added 35.69%	1,729,041 $10.7 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $7.2 Million - $9.76 Million	1,274,261 New	1,274,261 $8.81 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.